Its pleiotropic extrahypothalamic central actions and potential neuroprotective properties include the modulation of AD specific pathophysiological mechanisms (e.g., reduction of Aβ burden), thus making leptin a pharmaceutical target for the treatment of AD (Paz-Filho et al., 2010; McGuire and Ishii, 2016). This evidence concerns the gene LEP and Alzheimer disease.